Metropolis Healthcare
An Indian diagnostic-services company providing pathology testing, clinical laboratory services, wellness programs, and related healthcare solutions.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Metropolis Healthcare is an Indian diagnostic-services company whose principal business is the provision of pathology and clinical laboratory testing. Its activities span routine and specialized diagnostics, preventive health check packages, wellness testing, clinical research support, and laboratory-management services for hospitals and other healthcare institutions. The company is headquartered in Mumbai, Maharashtra, where it operates its central laboratory, and is identified in public references both as Metropolis Healthcare and Metropolis Labs. The business began in 1980 as a single diagnostic laboratory founded by Dr. Sushil Kanubhai Shah. A major transition took place in 2001, when Shah's daughter, Ameera Shah, took over the pathology business. Under her leadership, Metropolis pursued a partnership-led and acquisition-supported expansion model. Rather than relying only on wholly owned laboratories, it worked with local and regional diagnostic operators to increase geographic coverage and collection access. This approach helped it build a broad network across India while also supporting expansion into selected overseas markets. Metropolis began international expansion in 2005, entering Sri Lanka first. It subsequently expanded into the United Arab Emirates in 2006, Kenya in 2013, and Mauritius and Ghana in 2014. Publicly described network figures for 2018 referred to 124 clinical laboratories and approximately 2,400 collection centers across seven countries, including India, Ghana, Kenya, Mauritius, Sri Lanka, Zambia, and Uganda. Network size and geographic coverage can change over time, so those figures should be understood as historical rather than necessarily current operating totals. The company's service scope broadened during the 2010s beyond conventional diagnostic testing. Its stated or reported areas included clinical research, hospital laboratory management, wellness solutions, and health-awareness initiatives. Metropolis also participated in public-health programs. In 2018, it partnered with India's National AIDS Control Organisation on a three-year HIV-diagnosis project covering 560 locations. The company has also supported medical education and public outreach through initiatives such as the Medengage scholarship and mentorship program for medical students, the Conquer PCOS awareness campaign, and the Umbrella Handshake health-awareness campaign. Metropolis became a publicly listed company in April 2019. Before and around the listing, it had received institutional backing from investors including ICICI Venture, Warburg Pincus, Carlyle Group, CA Lotus Investments, and KKR-related investment vehicles. In October 2019, the company acquired four laboratories in Surat, Gujarat—Doctor's Clinical Laboratory, Iyer Pathology Laboratory, Nagar Pathology Laboratory, and Yash Clinical Laboratory—for reported consideration of INR 18 crore. The transaction was intended to deepen the presence of its subsidiary Desai Laboratories in the Surat market. In October 2021, Metropolis completed the acquisition of Hitech Diagnostic Centre and its subsidiary Centralab Healthcare Services, a transaction reported at approximately INR 636 crore, strengthening its position in southern India. The brand's market positioning is generally associated with organized, technology-enabled and relatively premium diagnostic care. Its customer base includes individual patients, physicians, hospitals, employers, and public-health institutions. The operating model combines central and regional laboratories with patient-facing collection centers and institutional services. Because the reference material does not provide a verified current corporate website, current executive roster, or current network count, those fields are left unconfirmed in this dossier.
History
Metropolis Healthcare originated in Mumbai in 1980, when Dr. Sushil Kanubhai Shah established a single diagnostic laboratory. The enterprise initially centered on pathology testing and laboratory diagnosis. In 2001, Shah's daughter, Ameera Shah, took over the pathology business and became the key figure in its subsequent expansion. During the following years, Metropolis developed a growth model based on partnerships with local and regional diagnostic chains, as well as the development of its own laboratory and collection infrastructure. This model enabled the company to extend its reach across India without relying exclusively on the construction of new standalone facilities. Over time, its activities expanded beyond routine pathology to include specialized testing, wellness solutions, clinical research, and hospital laboratory management. The company began international expansion in 2005, with Sri Lanka as its first overseas market. It entered the United Arab Emirates in 2006, Kenya in 2013, and Mauritius and Ghana in 2014. Public descriptions of the network in 2018 reported 124 clinical laboratories and approximately 2,400 blood-collection centers across seven countries, including India, Ghana, Kenya, Mauritius, Sri Lanka, Zambia, and Uganda. These figures describe the network at that historical point and are not treated here as a verified current count. Metropolis also developed relationships with public-health and professional organizations. In February 2018, it partnered with India's National AIDS Control Organisation on a three-year HIV-diagnosis program covering 560 locations. Its social and professional initiatives included Medengage, a scholarship and mentorship program launched in 2017 for undergraduate and postgraduate medical students, and public-awareness efforts addressing polycystic ovarian syndrome and general health. Institutional financing supported the company's expansion. ICICI Venture invested in Metropolis in 2006 through the India Advantage Fund. Warburg Pincus invested approximately US$85 million in 2010, after which the Shah family bought the exiting stake. Later investors and financial backers mentioned in public references include Carlyle Group, CA Lotus Investments and KKR-related entities. In 2015, KKR backed Ameera Shah through reported promoter debt funding. Metropolis became a listed company in April 2019. In the same year it pursued inorganic expansion in Gujarat, acquiring four individual laboratories in Surat for reported consideration of INR 18 crore. The laboratories were associated with the company's wholly owned subsidiary Desai Laboratories, and the transaction was intended to increase local penetration. In October 2021, Metropolis completed the acquisition of Hitech Diagnostic Centre and Centralab Healthcare Services for reported consideration of approximately INR 636 crore, expanding its presence in southern India. The company's history therefore reflects the development of an Indian laboratory business into a broader diagnostic network through family leadership, institutional investment, partnerships, international expansion, public listing and acquisitions. The available reference material does not establish a current executive roster, current ownership structure, or current facility count, so those matters require verification from contemporary company filings.
- 2021
Hitech Diagnostic Centre acquisition is completed
[1]Metropolis completes its acquisition of Hitech Diagnostic Centre and Centralab Healthcare Services.
- 2019
Metropolis becomes publicly listed
[1]The company goes public in India in April 2019.
- 2019
Four Surat laboratories are acquired
[1]Metropolis acquires four laboratories to strengthen Desai Laboratories' presence in Surat, Gujarat.
- 2018
HIV diagnosis partnership with NACO
[1]The company begins a three-year HIV-diagnosis project with India's National AIDS Control Organisation covering 560 locations.
- 2017
Medengage scholarship and mentorship program launches
[1]Metropolis launches a program for undergraduate and postgraduate medical students in India.
- 2014
Expansion into Mauritius and Ghana
[1]Metropolis adds Mauritius and Ghana to its international network.
- 2013
Expansion into Kenya
[1]The company enters Kenya as part of its overseas growth.
- 2006
Expansion into the United Arab Emirates
[1]Metropolis extends its international operations to the United Arab Emirates.
- 2005
International expansion begins in Sri Lanka
[1]Sri Lanka becomes Metropolis's first reported overseas market.
- 2001
Ameera Shah takes over the pathology business
[1]Ameera Shah assumes leadership of the pathology business and later drives its network expansion.
Products and positioning
Organized, broad-network and relatively premium diagnostic and pathology services provider serving consumers, physicians, hospitals, employers and public-health programs.
Diagnostic services · 1980
Pathology and clinical laboratory testing
The core offering consists of laboratory-based pathology and clinical diagnostic tests. The network serves individual patients and referring healthcare professionals through laboratories and collection centers. Public descriptions identify Metropolis as providing both routine and specialized testing, although the supplied sources do not provide a complete current test menu.
Preventive healthcare
Health check packages
Metropolis offers bundled health examinations intended to support preventive screening and general wellness assessment. These packages form part of its consumer-facing diagnostic proposition and complement individual pathology tests.
Specialized diagnostics
Specialized disease testing
The company provides specialized diagnostic testing for particular diseases and clinical conditions. The reference material does not specify a verified complete list of disease panels or testing technologies.
Institutional healthcare services
Hospital laboratory management
Hospital laboratory management is one of the service areas into which Metropolis expanded during the decade before the cited 2018 network description. It represents an institutional model in which the company supports laboratory operations for healthcare providers.
Wellness services
Wellness solutions
Wellness solutions extend the brand beyond illness-oriented diagnosis toward preventive monitoring and health assessment. Specific current programs and package names are not established by the supplied references.
Marketing campaigns
- 2018Umbrella Handshake
India
Metropolis initiated a health-awareness and public-outreach campaign supported by We Foundation and Red FM.
Outcome. The company reportedly donated INR 2 million toward this and other social-welfare initiatives; the supplied reference does not establish a standalone campaign outcome.
- 2017Medengage
India
Metropolis launched a scholarship and mentorship program for undergraduate and postgraduate medical students across India.
Outcome. The supplied reference describes the launch but does not provide independently verified participation or outcome data.
- 2017Conquer PCOS
India
Metropolis and the PCOS Society of India launched an awareness campaign focused on polycystic ovarian syndrome.
Outcome. The reference identifies the campaign and its public-awareness purpose but does not report quantified outcomes.
Brand decisions
2021
Acquire Hitech Diagnostic Centre and Centralab Healthcare ServicesM&ABackground
Metropolis pursued expansion in southern India through the acquisition of an established regional diagnostic chain.
Action taken
The company completed the acquisition of Hitech Diagnostic Centre and its subsidiary Centralab Healthcare Services.
Aftermath
The acquisition strengthened Metropolis's presence in South Indian diagnostic markets.
Reported acquisition consideration. INR 636 crore (October 2021)
2019
Acquire four Surat laboratoriesM&ABackground
Metropolis sought to increase the geographic reach of its wholly owned subsidiary Desai Laboratories in Surat, Gujarat.
Action taken
It acquired Doctor's Clinical Laboratory, Iyer Pathology Laboratory, Nagar Pathology Laboratory and Yash Clinical Laboratory.
Aftermath
The transaction expanded Metropolis's local laboratory presence in Surat.
Reported acquisition consideration. INR 18 crore (October 2019)
2005
Begin international expansionStrategyBackground
After developing its Indian diagnostic business, Metropolis sought to extend its laboratory network beyond India.
Action taken
The company entered Sri Lanka in 2005, followed by the United Arab Emirates, Kenya, Mauritius and Ghana in later years.
Aftermath
The overseas expansion created a multi-country diagnostic network, with historical references also listing operations or coverage in Zambia and Uganda.
Recent events
Metropolis Healthcare launches third MedEngage Scholarship edition[2]
Metropolis Healthcare announced the launch of the third edition of its MedEngage Scholarship programme and invited applications from final-year MBBS and MD/DNB students.
Metropolis Healthcare completes acquisition of Hitech Diagnostic Centre[3]
Reported:
Metropolis Healthcare completed its acquisition of 100% of Dr. Ganesan's Hitech Diagnostic Centre and its subsidiary Centralab Healthcare Services for Rs. 636 crore. Hitech became a wholly-owned subsidiary and Centralab became a step-down wholly owned subsidiary.
Metropolis Healthcare completes acquisition of Hitech Diagnostic Centre[4]
Reported:
Metropolis Healthcare announced that it had completed its all-cash acquisition of 100% of Dr. Ganesan's Hitech Diagnostic Centre and its subsidiary Centralab Healthcare Services for Rs. 636 crores.
Metropolis Healthcare launches NEXTGEN TB test[5]
Reported:
Metropolis Healthcare launched NEXTGEN TB, a whole-genome sequencing tuberculosis diagnostic test using an NGS platform to identify drug resistance and provide genetic information on resistance to up to 18 TB antibiotics.
Metropolis Healthcare partners with HaystackAnalytics on NEXTGEN TB[5]
Reported:
Metropolis Healthcare partnered with HaystackAnalytics in connection with the launch of NEXTGEN TB; the article described Metropolis as the first diagnostic service provider in India to launch NGS as a routine diagnostic test.
- Unconfirmed
Metropolis Healthcare completes acquisition of four Surat laboratories[6]
Reported:
Metropolis Healthcare completed the acquisition of Doctors Clinical Laboratory, Iyer Laboratory, Nagar Pathology Laboratory and Yash Laboratory in Surat, Gujarat. The acquisitions increased its laboratory count across eight Gujarat cities from 13 to 17.
Sources7 sources
- 1Metropolis Healthcareen.wikipedia.org
- 2Metropolis Healthcare启动第三届MedEngage奖学金计划biospectrumindia.com
- 3Metropolis Healthcare完成对Hitech Diagnostic Centre的收购business-standard.com
- 4Metropolis Healthcare 完成收购 Hitech Diagnostic Centreequitybulls.com
- 5Metropolis Healthcare 推出 NEXTGEN TB 检测health.economictimes.indiatimes.com
- 6Metropolis Healthcare完成收购苏拉特四家实验室divyabhaskar.co.in
- 7Metropolis Health completes acquisition of Hitechbusiness-standard.com
Cite this profile: Cite the canonical profile. /brand-wiki/metropolis-healthcare · Editorial policy · How profiles are compiled